This article has Open Peer Review reports available.
Recurrent corneal melting in the paraneoplastic pemphigus associated with Castleman’s disease
© The Author(s). 2016
Received: 22 July 2015
Accepted: 17 June 2016
Published: 12 July 2016
The ocular presentation of Castleman’s disease (CD)-associated paraneoplastic pemphigus (PNP) has rarely been reported. In this report, we describe a young patient with CD-associated PNP who had recurrent corneal ulceration in addition to cicatrizing conjunctivitis.
We describe a case of 23-year-old male with mucocutaneous erosion and conjunctival injection and erosion who was found to have PNP. Pelvic hyaline-vascular CD was detected and completely excised. The mucocutaneous lesions improved postoperatively. Two years after pelvic surgery, the patient gradually developed conjunctival symblepharon in both eyes and pterygium in the right eye. The patient then underwent a successful exclusion of the symblepharon, an excision of the pterygium and an amniotic membrane transplantation in the right eye. However, after 6 months, he experienced an aseptic corneal ulcer and recurrent pterygiumin the right eye. After treatment with systemic and local immunosuppressive medications, the corneal ulcer gradually healed and remained stable.
Corneal ulceration and melting, in addition to conjunctivitis, as a complication of CD-associated PNP, can be successfully managed with systemic and local immunosuppressants.
Paraneoplastic pemphigus (PNP) is a new autoimmune mucocutaneous blistering disease associated with neoplasms, such as Castleman’s disease (CD) [1–3]. PNP is characterized by distinctive clinical symptoms and signs, such as severe and painful mucosal erosions and polymorphous skin lesions [1, 2].
Cicatrizing conjunctivitis is the main ocular presentation of PNP , and only one case of bilateral corneal melting has been reported in a patient with PNP and a peripheral neuronal shaft tumor . However, the ocular involvement of CD-associated PNP has rarely been reported. In this report, we describe a young patient with CD-associated PNP who developed recurrent corneal ulceration in addition to conjunctivitis after the resection of the tumor.
In November 2011, a 23-year-old man presented with persistent, painful oral erosions resistant to systemic corticosteroid and antibiotic treatment. Conjunctival congestion and erosion was also present, but there were no other ocular abnormalities on slit-lamp and direct fundoscopic examinations. Local antibiotic eye drops and ointment were given. Erosion on the fingers in both hands appeared later.
In February 2014, 6 months after ocular surgery, the patient complained of pain and decreased vision in the right eye. A slit-lamp examination revealed conjunctival congestion, recurrent pterygium and a 2 mm-diameter aseptic corneal ulcer in the nasal-paracentral non-surgical area (Fig. 3b). There were no signs of ciliary injection and no conjunctival secretions. Initially, the administration of TobraDex eye drops every 2 h per day for 1 week and a bandage contact lens for 3 day failed to treat the corneal ulcer. Then, 0.1 % tacrolimus eye drops (prepared by the hospital) were prescribed instead of corticosteroid eye drops. The corneal ulcer gradually healed, with the remission of eye pain and an improvement in vision. However, once treatment with the tacrolimus eye drops was discontinued, the corneal ulcer recurred. Therefore, a topical 0.1 % tacrolimus twice per day and a 1 % cyclosporine ointment were prescribed. The same therapy was also applied to the left eye to treat a minor recurrence in the left eye. To date, the corneal melting has been stable for 6 months, with an intact epithelium, local corneal thinning and temporal pterygium in the right eye (Fig. 3c), as well as mild bilateral conjunctival congestion and posterior capsular lens opacity. A slight symblepharon developed in the left eye. The posterior capsular lens opacity was thought to be due to long-term systemic corticosteroid therapy, while the IOP in both eyes was normal. The patient was followed closely.
Currently, he is on systemic methylprednisone 16 mg daily, thalidomide 75 mg twice per day and methotrexate 10 mg weekly to treat oral erosions and ocular lesions. No evidence of tumor recurrence has been found on multiple follow-up pleural and abdominal CT and MRI scans. The results of routine laboratory testing have been normal. Autoantibodies against rat bladder transitional epithelium remain positive (with a low titer of 1:10).
Limited studies of CD-associated PNP have been reported. In addition, the ocular presentation has not been reported relating CD-associated PNP. Conjunctival injections and erosions have been mentioned in some cases of CD-associated PNP [7–9]. As far as we know, this report is the first that examines unilateral corneal ulceration and melting, in addition to cicatrizing conjunctival lesions, in CD-associated PNP.
The most common causes of corneal melting are infection, vitamin A deficiency, collagen vascular disease, severe Sjögren’s syndrome and neurotrophic keratitis . Each of these causes could be excluded in this patient, based on his medical history, his clinical symptoms and signs, and the results of the laboratory studies. Thus, an immunologic mechanism that arose directly from PNP might be associated with this patient’s corneal melting. However, the exact reason for the corneal melting and the relationship between CD-associated PNP and corneal melting remain to be elucidated.
CD is a rare neoplasm of lymphatic origin. The pathogenesis of CD-associated PNP remains unknown, although several hypotheses have been postulated, such as the secretion of autoantibodies from the tumor and the cross-reactivity of tumor antigens with epidermal antigens [2, 11]. Although a complete resection of a localized Castleman’s tumor could treat the disease and improve mucocutaneous lesions in most of patients [2, 7, 8], serum autoantibodies in some reports  and in this patient indeed remained detectable for as long as 2–4 years after surgery without recurrence of the tumor, suggesting that the immune reaction persisted. This might be the cause of the recurrence of mucosal lesions and the occurrence of corneal melting in this patient. It is necessary, therefore, to maintain effective immunosuppression for a prolonged postoperative period.
Currently, there is no standard therapy for conjunctival and corneal lesions from CD-associated PNP because of the rarity of this complication. As chronic cicatrizing conjunctivitis is more likely to occur in PNP, Tam et al.  proposed management with adequate lubrication, prophylactic antibiotics and corneal protection to reverse the underlying cause, to prevent symblepharon formation and to maintain the ocular surface. The successful local tacrolimus and cyclosporine treatment of corneal melting in the patient suggested that local immunosuppression in addition to systemic immunomodulatory therapy is critical for the treatment of corneal melting.
This case highlights the potential for CD-associated PNP to present with corneal ulceration, which may lead to blindness along period after the complete excision of localized neoplasms. Systemic and local immunosuppression administrations are essential for the treatment of corneal complications. Further studies are needed to elucidate the exact mechanism of corneal melting in CD-associated PNP.
CD, Castleman’s disease; IOP, intraocular pressure; PNP, paraneoplastic pemphigus
We thank numerous individuals participated in this study.
No funding was received for this study.
Availability of data and materials
All the data supporting the conclusions is included within the manuscript.
MW participated in the conception and design of the work, drafted the manuscript, participated in the follow-up of patient acquisition, performed in the analysis and interpretation of data, participated in figures selection and edition; manuscript revision and text editing; final manuscript critical revision and correction. SZ and LW performed clinical diagnosis, treatment and follow-up of patient, participated in the conception and design of the work, carried out the analysis and interpretation of data, participated in the final manuscript critical revision, and provided the clinical picture. HG participated in the follow-up of patient, acquisition, analysis and interpretation of data, in writing of the manuscript and text editing, and in the final manuscript critical revision and correction. YH and YL participated in the follow-up of patient, acquisition, analysis and interpretation of data, and in the final manuscript critical revision and correction. HZ performed histopathologic studies, carried out the analysis and interpretation of data and selection of histopathologic images, and participated in manuscript revision. QL performed MRI studies, carried out the analysis and interpretation of data and selection of MRI images, and participated in manuscript revision. All authors read and approved the final manuscript, and are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work were appropriately investigated and resolved.
The authors declare that they have no competing interests.
Ethics approval and consent to participate
The study protocol was approved by the Medical Ethics Committee of Sun Yat-sen Memorial Hospital, Sun Yat-sen University, and informed written consent was obtained from the patient. It also strictly adhered to the principles of the Declaration of Helsinki.
Written informed consent was obtained from the patient for publication of this Case report and any accompanying images. A copy of the written consent is available for review by the Editor of this journal.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Anhalt GJ, Kim SC, Stanley JR, Korman NJ, Jabs DA, Kory M, Izumi H, Ratrie H3rd, MutasimD, Ariss-AbdoL et al. An autoimmunemucocutaneous disease associated with neoplasia. N Engl J Med. 1990;323(25):1729–35.Google Scholar
- Yong AA, Tey HL. Paraneoplastic pemphigus. Australas J Dermatol. 2013;54(4):241–50.View ArticlePubMedGoogle Scholar
- CASE records of the Massachusetts General Hospital Weekly Clinicopathological Exercises: Case 40011. N Engl J Med. 1954; 250(1):26–30Google Scholar
- Laforest C, Huilgol SC, Casson R, Selva D, Leibovitch I. Autoimmune bullous diseases: ocular manifestations and management. Drugs. 2005;65(13):1767–79.View ArticlePubMedGoogle Scholar
- Beele H, Claerhout I, Kestelyn P, Dierckxens L, Naeyaert JM, De Laey JJ. Bilateral corneal melting in a patient with paraneoplastic pemphigus. Dermatology. 2001;202(2):147–50.View ArticlePubMedGoogle Scholar
- Camisa C, Helm TN. Paraneoplastic pemphigus is a distinct neoplasia-induced autoimmune disease. Arch Dermatol. 1993;129:883–6.View ArticlePubMedGoogle Scholar
- Wang J, Zhu X, Li R, Tu P, Wang R, Zhang L, Li T, Chen X, Wang A, Yang S, Wu Y, Yang H, Ji S. Paraneoplastic pemphigus associated with Castleman tumor: a commonly reported subtype of paraneoplastic pemphigus in China. Arch Dermatol. 2005;141(10):1285–93.View ArticlePubMedGoogle Scholar
- Fang Y, Zhao L, Yan F, Cui X, Xia Y, Duren A. A critical role of surgery in the treatment for paraneoplastic pemphigus caused by localized Castleman’s disease. Med Oncol. 2010;27(3):907–11.View ArticlePubMedGoogle Scholar
- Daneshpazhooh M, Oeineddin F, Kiani A, Naraghi ZS, Firooz A, Akhyani M, Chams-Davatchi C. Fatal paraneoplastic pemphigus after removal of Castleman’s disease in a child. Pediatr Dermatol. 2012;29(5):656–7.Google Scholar
- Knox Cartwright NE, Tole DM, Georgoudis P, Cook SD. Peripheral ulcerative keratitis and corneal melt: a 10-year single center review with historical comparison. Cornea. 2014;33(1):27–31.View ArticlePubMedGoogle Scholar
- Wang L, Bu D, Yang Y, Chen X, Zhu X. Castleman’s tumours and production of autoantibody in paraneoplastic pemphigus. Lancet. 2004;363(9408):525–31.View ArticlePubMedGoogle Scholar
- Nousari HC, Anhalt GJ. Pemphigus and bullous pemphigoid. Lancet. 1999;354:667–72.View ArticlePubMedGoogle Scholar
- Tam PM, Cheng LL, Young AL, Lam PT. Paraneoplastic pemphigus: an uncommon cause of chronic cicatrising conjunctivitis. BMJ Case Rep. 2009; 2009. doi:10.1136/bcr.12.2008.1306